Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Ibogaine is a monoterpene indole alkaloid derived from Tabernanthe iboga that has been used in medical and nonmedical settings to treat substance use disorders, most commonly for opioid detoxification. Earlier case series, uncontrolled reports and preclinical studies suggest ibogaine and its metabolite noribogaine can reduce opioid withdrawal signs and decrease self-administration of opioids and other drugs in animals, and some human reports have described prolonged abstinence in subsets of treated individuals. The compound’s pharmacology appears distinct from classical μ-opioid receptor agonists and NMDA antagonists, and proposed mechanisms include effects on GDNF expression and antagonism at α3β4 nicotinic receptors, although no single mechanism clearly explains the prolonged behavioural effects observed. This observational study set out to characterise detoxification outcomes and longer-term drug-use trajectories following ibogaine treatment in people with DSM-IV opioid dependence. Brown and colleagues report clinical and self-reported substance-use outcomes up to 12 months after treatment in a naturalistic sample treated at two private clinics in Baja California, Mexico, aiming to describe detoxification efficacy, subsequent changes in Addiction Severity Index Composite (ASIC) scores and subjective opioid withdrawal (SOWS) ratings, and to identify baseline features associated with more favourable outcomes.

This was an observational, naturalistic follow-up study approved by the California Institute of Integral Studies’ Human Research Review Committee. Treatment occurred as usual at two fee-for-service private clinics in Ensenada (n = 25) and Playas de Tijuana (n = 5), Mexico; the investigators did not administer treatment. Thirty participants meeting DSM-IV criteria for Opioid Dependence with physiological dependence were enrolled after giving informed consent. Exclusion criteria included prior ibogaine treatment, using ibogaine for reasons other than OUD, or any condition judged by the investigator to preclude study participation. Participants were required to provide a corroborating contact and to have reliable means of communication; follow-up interviews were incentivised with small gift certificates. Clinical treatment procedures reflected provider practice rather than a fixed research protocol. Subjects were stabilised on short-acting opioids (typically oxycodone) for two to three days before ibogaine. A mean total dose of 1,540 ± 920 mg ibogaine HCl (94% purity) was administered; 27% of subjects (5/30) also received crude Tabernanthe iboga root-bark extract. Providers used a test–flood–booster dosing strategy: a test dose of approximately 3 mg/kg given when early withdrawal signs appeared, a larger flood dose (~4× the test dose) 2–12 hours later, and optional booster doses of 3–5 mg/kg up to 1–16 hours thereafter. Monitoring included EKG, pulse oximetry, blood pressure, intravenous access and an ACLS-certified medical professional present for at least the first 24 hours. No opioids or ancillary medications were administered after initiating ibogaine. Assessments included the 16-item Subjective Opioid Withdrawal Scale (SOWS) administered at baseline (within one hour before the test dose) and at a post-treatment timepoint determined by the provider (mean 76.5 ± 30 hours after baseline), and the ASI Lite at baseline and at 1, 3, 6, 9 and 12 months. The ASI Lite yields seven ASIC scores (Drug Use, Alcohol Use, Family/Social, Employment, Legal, Medical, Psychiatric), each scaled 0–1. Follow-up interviews were conducted by the first author in person or by telephone, and corroborative contacts were sought. The analysis used paired t-tests to compare pre- versus posttreatment SOWS and ASIC scores, and noninferiority tests to assess whether the 1-month treatment effect was maintained at later time points. To conservatively handle missing follow-up data, missing posttreatment values were set equal to pretreatment baseline values in the adjusted analyses.

Thirty subjects were enrolled (25 males, 5 females), most reporting heroin (n = 14) or prescription opioid analgesics, primarily oxycodone (n = 10), as their principal problematic drugs. Participants reported heavy opioid use in the prior 30 days (mean 29.0 ± 3.2 days), averaging 5.2 ± 3.0 consecutive years of regular opioid use. Mean daily amounts when using were 1.3 ± 0.94 g/day for heroin and 250 ± 180 mg/day for oxycodone. Nearly all subjects (97%) had prior treatment for substance use, with a mean of 3.1 ± 2.6 prior episodes. Detoxification outcomes: SOWS scores (n = 27 with paired SOWS) fell from 31.0 ± 11.6 at baseline to 14.0 ± 9.8 at the post-treatment assessment, a mean reduction of 17.0 ± 12.5 points (t = 7.07, df = 26, p < .001). The mean interval between baseline and the posttreatment SOWS was 76.5 ± 30 hours. The decrease in SOWS did not differ significantly between participants with and without comorbid non-opioid substance use. ASI/ASIC outcomes and opioid use: At 1 month after treatment, 15 of 30 subjects (50%) reported no opioid use in the prior 30 days; at 3 months this was 10 of 30 (33%). Group-level paired t-tests comparing ASIC scores to baseline (with missing values conservatively set to baseline) showed significant improvements relative to pretreatment for Drug Use (p < .001 at 1, 3, 6, 9 and 12 months), Family/Social Status (p < .001 at 1, 3, 9 and 12 months; p < .01 at 6 months), and Legal Status (p-values ranging from < .01 to < .05 across time points). Alcohol Use and Medical Status ASIC scores did not change significantly at any time point. Psychiatric Status showed a marginal decrease at 1 month (p = .053) and significant improvements at 3 months (p < .05) and 6 months (p < .01). Employment Status increased at 1 month (p < .01) but did not differ at later time points. Noninferiority testing used the 1-month ASIC values (n = 20 available at 1 month) as reference to evaluate whether subsequent scores were not worse by a prespecified margin (≥0.1 ASIC point). Family/Social and Legal Status scores met noninferiority criteria at several later time points (Family/Social p < .01 at 3, 6 and 9 months; Legal p < .01 at 3 and 9 months and p < .05 at 6 and 12 months), indicating sustained benefit versus 1 month. The Drug Use noninferiority tests were not significant under the conservative missing-data adjustment, implying the 1-month Drug Use improvement was not demonstrably equivalent to later timepoints when assuming missing subjects had returned to baseline; however, unadjusted analyses (excluding the conservative assumption) yielded significant noninferiority for Drug Use at all time points, consistent with a sustained effect in a subset rather than uniformly across the sample. Individual trajectories plotted by the authors suggested a subgroup with large, durable Drug Use score reductions through 12 months. Predictors and additional treatments: A subgroup of 12 subjects met criteria for favourable outcome (retained at 9 or 12 months with ≥75% reduction in Drug Use score). This subgroup did not differ from others on most baseline demographics or substance-use variables but had fewer prior treatment episodes (mean 2.0 ± 1.6) than the less favourable group (mean 3.8 ± 2.9; t = 2.16, df = 27.3, p = .041). Prior exposure to methadone (either recent use or history of maintenance) was associated with less favourable outcome (Fisher’s Exact p = .002); buprenorphine exposure was not associated with outcome. During the 12-month follow-up, 9 subjects received additional SUD treatments (residential n = 4, opioid agonist maintenance n = 3, repeat ibogaine n = 3). Analyses treated residential-treatment intervals conservatively as missing and imputed to baseline. Adverse events: Within this study no clinically significant cardiovascular or other medical events were observed. The authors nonetheless note that fatalities have been reported elsewhere and discuss cardiac arrhythmia risks associated with ibogaine and noribogaine (hERG channel blockade, polymorphic ventricular tachycardia and torsade de pointes), and that the structural analogue 18-MC shows less hERG blockade in preclinical testing.

Brown and colleagues interpret the findings as consistent evidence that ibogaine was associated with marked short-term reduction in subjective opioid withdrawal and with substantive reductions in drug-use measures at 1 month, with sustained improvements in certain domains and in a subset of individuals up to 12 months. The magnitude of SOWS reduction (mean 17 points) is compared by the authors to reductions observed with methadone in prior work, and the authors emphasise that 50% of subjects reported no opioid use at 1 month—considerably higher than typical abstinence rates reported after conventional detoxification without maintenance pharmacotherapy. The investigators highlight that improvements were most robust at 1 month, that group-level Drug Use scores remained improved versus baseline across subsequent time points, but that noninferiority testing under conservative missing-data assumptions did not demonstrate equivalence of later time points to the 1-month effect. They therefore infer a pattern in which a subgroup of responders exhibit durable benefit while others relapse or do not maintain the initial gains. The subgroup with favourable outcomes had fewer prior treatment episodes and less exposure to methadone, and the authors note the inability of the available data to disentangle whether methadone exposure per se or greater overall prior treatment history mediated poorer outcome. The authors acknowledge multiple limitations that constrain causal inference and generalisability: the observational, uncontrolled design; small sample size and substantial attrition; reliance on self-report without biological verification; heterogeneity in dosing intervals; and potential confounding by subsequent treatments received during follow-up. They also note that the mean posttreatment SOWS assessment occurred at about 76.5 hours after baseline, an interval that overlaps with the expected natural time course of unassisted opioid withdrawal (commonly 48–72 hours to peak, but variable), which could lead to overestimating treatment-specific effects on withdrawal. Safety concerns are discussed candidly: although no serious events occurred in this cohort, ibogaine has been implicated in fatalities linked to cardiac arrhythmias through hERG blockade, and the authors suggest 18-MC as an example of a related molecule with a potentially improved cardiac safety profile. Finally, the investigators describe qualitative reports from participants of psychologically salient, often autobiographical experiences during treatment (the so-called "slide show") and suggest these subjective effects may relate to observed improvements in Family/Social functioning. They argue that the iboga alkaloid scaffold could serve as a prototype for rational drug design to separate therapeutic from toxic liabilities and recommend adequately powered, controlled clinical trials with laboratory verification of outcomes to formally evaluate ibogaine or structural derivatives as candidates for addiction pharmacotherapy.

Within the constraints of an uncontrolled observational study, ibogaine was associated with a substantive effect on opioid withdrawal and with reduced drug use at 1 month, with sustained reductions up to 12 months in a subgroup of participants. The authors conclude that ibogaine may have clinical utility for some individuals who have failed other treatments for OUD and that the iboga alkaloid scaffold offers a pharmacologically interesting template for future drug discovery. They emphasise the need for rigorous randomised trials and rational medicinal chemistry to develop compounds that retain potential therapeutic effects while minimising cardiac and other risks.